Enovis Corp Ordinary Shares ENOV 深 滬
交易中 09-20 13:50:14 美东时间
43.97
-1.050
-2.33%
華盛通- 最 高44.58
- 今 開44.43
- 成交量 17.05万股
- 最 低 43.42
- 昨 收 45.02
- 總市值 24.02亿
- 52周最高 65.03
- 市盈率 靜 --
- 換手率 0.31%
- 52周最低 39.98
- 委 比 0.00%
- 總股本 5461.98万
- 歷史最高 176.11
- 量 比 0.39
- 振 幅 2.58%
- 歷史最低 -13.31
- 每 手 1
- 風險率 6.23%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多ENOVA ANNOUNCES NEW $300 MILLION SHARE REPURCHASE PROGRAM
CHICAGO, Aug. 12, 2024 /PRNewswire/ -- Enova International, Inc. (NYSE: ENVA) ("Enova" or the "Company"), a leading financial services company powered by machine learning and world-class ana...
08-13 04:16
Goldman screens for post-selloff stocks with healthy fundamentals at a discount
Investor attention will shift away from macro following a volatile week, but stock-picking opportunities will remain, according to Goldman Sachs. Concerns over a weak labor market prompted selling in ...
08-12 04:04
Wells Fargo Remains a Buy on Enovis (ENOV)
In a report released yesterday, Vik Chopra from Wells Fargo maintained a Buy ra...
08-08 19:19
Needham Maintains Buy on Enovis, Lowers Price Target to $65
Needham analyst Mike Matson maintains Enovis (NYSE:ENOV) with a Buy and lowers the price target from $82 to $65.
08-08 18:20
Top 3 Health Care Stocks That Could Blast Off In June
The most oversold stocks in the health care sector presents an opportunity to b...
06-21 20:22
Enovis Corporation beats top-line and bottom-line estimates; updates FY24 outlook
Enovis Corporation press release (NYSE:ENOV): Q1 Non-GAAP EPS of $0.50 beats by $0.02. Revenue of $516M (+27.0% Y/Y) beats by $10.41M. Adjusted EBITDA of $83 million, or 16.1% of sales on a reported b...
05-02 18:14
Needham sees BSX, CNMD, RMD beating Street, despite medtech slow down
Needham estimates medtech sales grew less than expected in Q1, but that Boston Scientific (NYSE:BSX), CONMED (NYSE:CNMD), ResMed (NYSE:RMD) and Surmodics (NASDAQ:SRDX) should still be able to beat the...
04-15 05:56
Needham：重申Enovis(ENOV.US)评级，由买入调整至买入评级, 目标价82.00美元。
Needham：重申Enovis(ENOV.US)评级，由买入调整至买入评级, 目标价82.00美元。
04-10 20:20
2024年仅增长4.8%？ Needham谨慎看待骨科器械市场复苏
华尔街知名投资机构Needham的一项最新分析显示，不要指望与疫情相关的手术积压会推动今年骨科医疗器械的销售。该行表示，积压的手术数量似乎已基本归零，2023年...
04-01 14:40
Don't expect pandemic backlog to fuel orthopedic sales, says Needham
Don’t expect a pandemic-related backlog in procedures to fuel sales of orthopedic medical devices this year, according to a new analysis by Needham & Co. In a recent report, the investment bank said t...
04-01 07:46
